Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04697706 · ClinicalTrials.gov registry record · Early Phase 1
Effect of a High Citrate Beverage on Urine Chemistry in Urinary Stone Disease
A Early Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT04697706: Completed Early Phase 1 study, sponsored by NYU Langone Health.
NCT04697706 is a Early Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 6 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04697706, a Early Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will investigate the effect of a patented high citrate beverage on urine chemistry in patients with urinary stone disease (USD). It is a minimal risk study of an over-the-counter beverage called Moonstone, which is commercially available. This study is considered preparatory for the RO-1 and is not intended to produce a definitive outcome regarding kidney stones.
Primary Outcome
In calcium stone formers, the effect of Moonstone on urine citrate excretion will be compared to that of water in a non-inferiority analysis.
Interventions
- OTHER Water
- DIETARY_SUPPLEMENT Moonstone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2020-12-14 |
| Phase | Early Phase 1 |
What the finished NCT04697706 record still lists
NCT04697706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Water is the first listed.
NCT04697706 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04697706 about?
NCT04697706 is a clinical study titled "Effect of a High Citrate Beverage on Urine Chemistry in Urinary Stone Disease". This study will investigate the effect of a patented high citrate beverage on urine chemistry in patients with urinary stone disease (USD). It is a minimal risk study of an over-the-counter beverage called Moonstone, which is commercially available. This study is considered preparatory for the RO-1 ...
What is the current status of trial NCT04697706?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2020-09-01. Estimated completion is 2020-12-14.
What interventions are being tested in trial NCT04697706?
The interventions under investigation include: Water (OTHER), Moonstone (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04697706?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04697706's enrollment target sits among peer trials
6 1846th of 2000 higher than 114 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI